Clinical trial · Observational
National, Multicentric Registry Study on Neuroimmunological Diseases in China
NCT06443333CI-TRIAL-00077744NIDBaseunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to establish a real-world clinical neuroimmune disease research cohort, to follow up and observe the prognosis of patients with different subtypes and subgroups, and to provide support for the treatment, early warning, and outcome prediction research of neuroimmune diseases.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Disseminated Encephalomyelitis | — | UNRESOLVED | — |
| Autoimmune Encephalitis | — | UNRESOLVED | — |
| Multiple Sclerosis | — | UNRESOLVED | — |
| Myasthenia Gravis | — | UNRESOLVED | — |
| Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | — | UNRESOLVED | — |
| NMO Spectrum Disorder | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
| Data collection and follow-up observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- neuroimmune diseases patient
- description
- Patients diagnosed with neuroimmune diseases by a neurologist.
- interventionNames
- Other: Data collection and follow-up observation
- label
- Health Volunteers
- description
- Healthy adults undergoing medical examinations at the Xuanwu Hospital Physical Examination Center.
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Annual recurrence rate
- timeFrame
- At 12 and 24 months after enrollment
- description
- Whether there is recurrence in patients followed up at 12 and 24 months after enrollment
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients who diagnosed at Xuanwu Hospital, Capital Medical University with any of the following conditions: * Multiple Sclerosis (the criteria followed the Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria) * NMO Spectrum Disorder (the criteria followed the Diagnosis and Treatment Guidelines for Optic Neuromyelitis Spectrum Disorders in China 2016) * Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (the criteria followed the Consensus of Chinese Experts on Diagnosis and Treatment of Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Diseases) * Myasthenia Gravis (the criteria followed the Guidelines for the Diagnosis and Treatment of Myasthenia Gravis in China 2020) * Autoimmune Encephalitis (the criteria followed the China Expert Consensus on Diagnosis and Treatment of Autoimmune Encephalitis 2017) * Acute Disseminated Encephalomyelitis (the criteria are based on the article titled "Acute disseminated encephalomyelitis" 2007). * Healthy adults who underwent a physical examination at the Physical Examination Center of Xuanwu Hospital, Capital Medical University Exclusion Criteria: * Women during pregnancy or lactation. * Patients with other neurological diseases or serious mental diseases. * Patients with serious liver and kidney function or other important organ dysfunction. * Unable to cooperate with follow-up work and venous blood collection due to poor compliance of patients or healthy volunteers, or incomplete clinical and imaging data.
References
Publications (1)
- DERIVEDZhang M, Han J, Xia J, Lin M, Chen T, Ruan S, Wang Q, Men Y, Gao R, Zheng H, Li J, Qi Y, Chen S, Wang Y, Tang Y, Li D, Yang X, Qiu Z, Liu Z, Dong H, Zhao Y, Hao J. Chinese neuroimmunological disease (NIDBase) cohort study: cohort profile. BMJ Open. 2026 Jan 8;16(1):e099386. doi: 10.1136/bmjopen-2025-099386. PMID 41506767